vimarsana.com

Page 53 - அமெரிக்கன் கலைக்கழகம் ஆஃப் நரம்பியல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Avidity Biosciences to Present Oral Presentation on AOC 1001 for DM1 at American Academy of Neurology (AAN) 2021 Virtual Annual Meeting

Avidity Biosciences to Present Oral Presentation on AOC 1001 for DM1 at American Academy of Neurology (AAN) 2021 Virtual Annual Meeting News provided by Share this article Share this article LA JOLLA, Calif., April 16, 2021 /PRNewswire/ Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs ™), today announced that preclinical data for their lead candidate, AOC 1001 in development for myotonic dystrophy type 1 (DM1), will be presented at the American Academy of Neurology (AAN) 2021 Virtual Annual Meeting being held April 17-22, 2021.  The abstract on AOC 1001 was chosen by the AAN Science Committee as one of 11 abstracts to be highlighted in the Emerging Science Session.

Blood-Based Markers Tied to Brain Cell and Memory Loss

email article Two proteins in blood plasma neurofilament light chain (NfL) and total tau were associated with cognition and neuroimaging outcomes, strengthening their potential as blood-based biomarkers of neurodegeneration, a large longitudinal study showed. At baseline, NfL was more strongly associated with brain atrophy in multiple areas, white matter alterations, and changes in global cognition, reported Michelle Mielke, PhD, of the Mayo Clinic in Rochester, Minnesota. The combination of elevated NfL and total tau at baseline was more strongly associated with worse global cognition and memory loss and with neuroimaging measures, including temporal cortex thickness and increased number of infarcts.

Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS

Evobrutinib is the First and Only BTK Inhibitor to Demonstrate Reduction of a Key Biomarker of Neuronal Damage and Inflammation in Patients with MS
financialbuzz.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialbuzz.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.